Direxion Daily Pharmaceutical & Medical Bull 3X ETF
PILL
2 hedge funds and large institutions have $1.37M invested in Direxion Daily Pharmaceutical & Medical Bull 3X ETF in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
4.87% less ownership
Funds ownership: 16.03% → 11.15% (-4.9%)
47% less capital invested
Capital invested by funds: $2.59M → $1.37M (-$1.22M)
60% less funds holding
Funds holding: 5 → 2 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$491K |
| 2 |
XS
XR Securities
Chicago,
Illinois
|
-$348K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
-$231K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$154K |
PILL Hedge Fund Activity: Q3 2020 in Review
2 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) for Q3 2020, worth a combined $1.37M — down 47% from $2.59M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PILL and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $491K sold.
- 2 institutional investors held Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) as of Q3 2020, down from 5 in Q2 2020.
- Funds reported $1.37M of Direxion Daily Pharmaceutical & Medical Bull 3X ETF stock for Q3 2020, down 47% quarter-over-quarter.
- 0 funds opened new Direxion Daily Pharmaceutical & Medical Bull 3X ETF positions in Q3 2020 and 3 closed out, a net change of -3 holders.
- The largest Direxion Daily Pharmaceutical & Medical Bull 3X ETF seller in Q3 2020 was Tower Research Capital (TRC), an estimated $491K sold.
Based on aggregated 13F filings for Q3 2020.